Canopy Growth: Analysts Expect Q2 Revenues Of $142.5 Million

Canopy Growth Corp (TSX: WEED) (NASDAQ: CGC) announced that they will be reporting their fiscal second quarter financials before market open on November 5th.

Analysts have a consensus C$26.94 12-month price target on the company, via a total of 14 analysts, with 2 analysts having buy ratings, 11 have holds and 1 analyst has a strong sell rating on the stock. Nine analysts have a hold rating and two analysts have a strong sell rating. The street high comes from MKM Partners with a C$51 price target, and the lowest target comes from Stifel-GMP with a C$15 price target.

13 analysts have revenue estimates for the second quarter. The mean between all 13 is C$142.49 million; this number has been revised downwards from C$191.25 million at the start May. The street high is C$173.10 million while the lowest sits at C$130 million.

Six analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 21.42%, with this number being revised downwards from 34.30% at the start of May. Street high goes to CIBC Capital Markets with a 26.50% estimate and the lowest sits at 16%.

Onto EBITDA estimates, there are currently 12 analysts who have second quarter EBITDA estimates. The mean is currently (C$52.35) million, with this number being lower at the start of May. Street high goes to Benchmark with a (C$36) million EBITDA estimate and the lowest being a (C$67.3) million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

A $2.2B Gold Project Is Outgrowing Its Plan | Michael Henrichsen – Gold X2 Mining

Pay for the Copper, Get the Gold Free | Rob McEwen – McEwen Inc

This Gold Discovery Was Already Huge. Now It’s Becoming a Monster. | Goliath Resources

Recommended

This Gold Discovery Just Keeps Getting Bigger | Roger Rosmus – Goliath Resources

Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early

Related News

Cronos: Raymond James Remains Bullish Despite Revenue Miss

Cronos Group (TSX: CRON) (NASDAQ: CRON) reported its first-quarter financial results on Friday, May 7th....

Tuesday, May 11, 2021, 05:47:00 PM

Aphria: Consensus Estimates For Q3 2021

Aphria Inc (TSX: APHA) (NASDAQ: APHA) is expected to report their fiscal third quarter on...

Wednesday, April 7, 2021, 02:41:00 PM

Canopy Growth Sells BioSteel Assets For $30.4 Million

Canopy Growth (TSX: WEED) has unsurprisingly taken a loss on its investment into BioSteel, with...

Friday, December 1, 2023, 09:09:45 AM

Yamana Gold: Stifel, Canaccord Issue Flash Update Following Preliminary Results

This morning Canaccord Genuity and Stifel GMP released a flash update on Yamana Gold (TSX:...

Thursday, October 8, 2020, 01:13:00 PM

Lundin Gold Sees BMO Capital Markets Raise 2022 Production Estimates

Last week, Lundin Gold Inc. (TSX: LUG) announced its second-quarter production results. The company said...

Monday, July 11, 2022, 02:18:00 PM